San Diego, CA, United States
San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | July 25, 2017
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced that its proprietary multipotent cell conditioned media will be marketed by leading global biopharmaceutical company Allergan within its recently-acquired Regenica® Advanced Rejuvenation System. The Multipotent Resignaling Complex (MRCx™) within Regenica is made up of soluble cell-signaling proteins and growth factors which support the body’s epidermal stem cells that renew skin throughout life. Through Histogen’s technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce these proteins associated with skin renewal. “Histogen has developed a next-generation regenerative cell technology, harnessing the power of growth factors and stem-cell signaling molecules for skin rejuvenation that complements Allergan’s flagship growth factor technology - TNS,” said Rahul Mehta, Ph.D., Vice President, Research & Development at SkinMedica, an Allergan Company. “In addition to the Regenica product line, we are looking forward to collaborating with Histogen and leveraging their science to further bolster SkinMedica’s commitment to evidence-based skincare.” First created at Histogen as a three-product line for anti-aging and post-resurfacing, Regenica was licensed by Suneva Medical in 2012 and has grown to the current Advanced Rejuvenation System of six products sold through medical aesthetic professionals throughout the world. The acquisition of the product line by Allergan now expands the reach of the technology. “Allergan's world-class medical aesthetics portfolio, global footprint, history and commitment to developing innovative aesthetic products makes them ideally suited to realize the maximum potential of the Regenica growth factor technology for continued innovation in skincare,” said Dr. Gail Naughton, Histogen founder and inventor of its core technology. Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension. Through this unique technology process, newborn cells are directed to naturally produce vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit www.histogen.com.


The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.


The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.


News Article | November 12, 2016
Site: www.PR.com

Receive press releases from San Diego Advisor of the Year: By Email Advisor of the Year Recognizes 2016 Award Winners at Second Annual Event Leading business professionals in San Diego honored for stellar leadership and outstanding accomplishments in the M&A community San Diego, CA, November 12, 2016 --( Feted were the following: · Andrew Ruff, TGC Accounting (Sell-side preparation by a CPA firm), · Bruce Strumlauf, LevitZacks (Financial and tax strategy for a deal over $25 million), · Channing Hamlet, Objective Capital Partners (Sell-side investment banking over $25 million) · Cheston Larson, Latham & Watkins (Sell-side legal representation to a public company – Deal size over $25 million) · David Noosinow, BNY Mellon (Long-term exit planning) · Hayden Trubitt, Stradling, Yocca Carlson & Rauth (Sell-side legal representation to a private company – Deal size over $25 million) · John D. Tishler, SheppardMullin (Advice for an internal transition – Deal size under $25 million) · Michael Brown, Stradling Yocca Carlson & Rauth (Sell-side legal representation to a private company – Deal size under $25 million) · Mike Friedman, LevitZacks (Financial and tax strategy for a deal under $25 million) · Michel Kim, Objective Capital Partners (Internal transition advice), · Nancy G. Henderson, Henderson Caverly Pum & Charney (Pre-transaction planning), · Patrick Monroe, Best Best & Krieger (Buy-side legal representation – Deal under $25 million) · Paul Johnson, Procopio (Sell-side legal representation in sale to a public company – Deal size under $25 million) · Steve LaSala, SheppardMullin (Buy-side legal representation – Deal size over $25 million) · Todd Wilson & Joel Weinstein, W Partners (Buy-side investment banking & growth capital design and execution) · Trever Acers, Objective Capital Partners (Advice for internal transition – Deal size under $25 million) · Wade Hansen, Cabrillo Advisors (Sell-side investment banking – Deal size under $25 million). “Advisor of the Year is especially proud to announce the winners of this year’s awards,” says Paul Thiel, managing director of BNY Mellon’s San Diego practice. “This recognition shines a light on the deserving people behind the impressive deals in San Diego’s M&A community.” The judging panel was led by former Broadcom chairman John Major and Histogen founder and CEO Gail Naughton, and included representatives from UCSD’s Rady School of Management, CSU San Marcos’ School of Business and the La Jolla Institute, as well as several entrepreneurs who have successfully navigated the M&A process. In addition to the recognition, select winners will be invited to participate as featured speakers at subsequent events, including the Association for Corporate Growth conference, “The Deals Behind the Advisor of the Year,” to be held at Lomas Santa Fe Country Club on Tuesday, November 15. A major highlight of the 2016 Advisor of the Year event was the lively “GameChangers: Women in the C-Suite” session. Moderated by Emily Rex, CEO of Departure, the panel featured San Diego’s police chief Shelley Zimmerman, the San Diego Chargers’ Jeanne Bonk, Port Brewing Company’s Gina Marsaglia and leadership consultant Cindy Candela sharing their personal experiences working - and succeeding - in traditionally male-dominated industries. Local legendary entrepreneur Ernest Rady delivered an impactful keynote address. Net proceeds from the event will benefit the Institute. “We’d like to thank everyone who attended and took part in making this year’s Advisor of the Year event a big success,” says Thiel. “We also are grateful to our sponsors and look forward to continuing to bring attention to the great work that is happening daily in San Diego’s business community.” Sponsors of the 2016 Advisor of the Year program are: BDO; Best Best & Krieger; Cabrillo Advisors; CBIZ; Claiborne Advisors; Deloitte; Departure; Friedman Brannen; Haskell & White; Henberger Group; HetzelMeade Communications; LevitZacks CPA, Lindsay & Brownell; NFP Insurance Brokerage & Consulting; Objective Capital Partners; Our City magazine; Polito Eppich; Procopio; RA Capital Advisors; Stradling; SheppardMullin; Torrey Pines Bank; Vantage Point Advisors and W Partners. About Advisor of the Year Advisor of the Year is a not-for-profit unincorporated community association that hosts an annual awards event to recognize and celebrate local advisors who provide extraordinary service and value to owners of middle market companies in the sale, expansion or recapitalization of their companies. The organization also conducts educational workshops and commissions primary research on business and financial trends that affect advisors and their clients. Select winners will be featured in the November ACG program, “The Deals Behind the Advisor of the Year awards.” About La Jolla Institute La Jolla Institute for Allergy and Immunology is located at 9420 Athena Circle in La Jolla and is dedicated to understanding the intricacies and power of the immune system to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease®. San Diego, CA, November 12, 2016 --( PR.com )-- The San Diego Advisor of the Year organization today announced the winners of its annual awards recognizing individuals who displayed extraordinary service in supporting the sale, acquisition or recapitalization of a company on behalf of their clients. The recipients were named during the annual awards program and ceremony, hosted by title sponsor BNY Mellon Wealth Management and held at the world-renowned La Jolla Institute for Allergy and Immunology on October 27.Feted were the following:· Andrew Ruff, TGC Accounting (Sell-side preparation by a CPA firm),· Bruce Strumlauf, LevitZacks (Financial and tax strategy for a deal over $25 million),· Channing Hamlet, Objective Capital Partners (Sell-side investment banking over $25 million)· Cheston Larson, Latham & Watkins (Sell-side legal representation to a public company – Deal size over $25 million)· David Noosinow, BNY Mellon (Long-term exit planning)· Hayden Trubitt, Stradling, Yocca Carlson & Rauth (Sell-side legal representation to a private company – Deal size over $25 million)· John D. Tishler, SheppardMullin (Advice for an internal transition – Deal size under $25 million)· Michael Brown, Stradling Yocca Carlson & Rauth (Sell-side legal representation to a private company – Deal size under $25 million)· Mike Friedman, LevitZacks (Financial and tax strategy for a deal under $25 million)· Michel Kim, Objective Capital Partners (Internal transition advice),· Nancy G. Henderson, Henderson Caverly Pum & Charney (Pre-transaction planning),· Patrick Monroe, Best Best & Krieger (Buy-side legal representation – Deal under $25 million)· Paul Johnson, Procopio (Sell-side legal representation in sale to a public company – Deal size under $25 million)· Steve LaSala, SheppardMullin (Buy-side legal representation – Deal size over $25 million)· Todd Wilson & Joel Weinstein, W Partners (Buy-side investment banking & growth capital design and execution)· Trever Acers, Objective Capital Partners (Advice for internal transition – Deal size under $25 million)· Wade Hansen, Cabrillo Advisors (Sell-side investment banking – Deal size under $25 million).“Advisor of the Year is especially proud to announce the winners of this year’s awards,” says Paul Thiel, managing director of BNY Mellon’s San Diego practice. “This recognition shines a light on the deserving people behind the impressive deals in San Diego’s M&A community.”The judging panel was led by former Broadcom chairman John Major and Histogen founder and CEO Gail Naughton, and included representatives from UCSD’s Rady School of Management, CSU San Marcos’ School of Business and the La Jolla Institute, as well as several entrepreneurs who have successfully navigated the M&A process.In addition to the recognition, select winners will be invited to participate as featured speakers at subsequent events, including the Association for Corporate Growth conference, “The Deals Behind the Advisor of the Year,” to be held at Lomas Santa Fe Country Club on Tuesday, November 15.A major highlight of the 2016 Advisor of the Year event was the lively “GameChangers: Women in the C-Suite” session. Moderated by Emily Rex, CEO of Departure, the panel featured San Diego’s police chief Shelley Zimmerman, the San Diego Chargers’ Jeanne Bonk, Port Brewing Company’s Gina Marsaglia and leadership consultant Cindy Candela sharing their personal experiences working - and succeeding - in traditionally male-dominated industries. Local legendary entrepreneur Ernest Rady delivered an impactful keynote address. Net proceeds from the event will benefit the Institute.“We’d like to thank everyone who attended and took part in making this year’s Advisor of the Year event a big success,” says Thiel. “We also are grateful to our sponsors and look forward to continuing to bring attention to the great work that is happening daily in San Diego’s business community.”Sponsors of the 2016 Advisor of the Year program are: BDO; Best Best & Krieger; Cabrillo Advisors; CBIZ; Claiborne Advisors; Deloitte; Departure; Friedman Brannen; Haskell & White; Henberger Group; HetzelMeade Communications; LevitZacks CPA, Lindsay & Brownell; NFP Insurance Brokerage & Consulting; Objective Capital Partners; Our City magazine; Polito Eppich; Procopio; RA Capital Advisors; Stradling; SheppardMullin; Torrey Pines Bank; Vantage Point Advisors and W Partners.About Advisor of the YearAdvisor of the Year is a not-for-profit unincorporated community association that hosts an annual awards event to recognize and celebrate local advisors who provide extraordinary service and value to owners of middle market companies in the sale, expansion or recapitalization of their companies. The organization also conducts educational workshops and commissions primary research on business and financial trends that affect advisors and their clients. Select winners will be featured in the November ACG program, “The Deals Behind the Advisor of the Year awards.”About La Jolla InstituteLa Jolla Institute for Allergy and Immunology is located at 9420 Athena Circle in La Jolla and is dedicated to understanding the intricacies and power of the immune system to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease®. Click here to view the list of recent Press Releases from San Diego Advisor of the Year


News Article | February 15, 2017
Site: www.prweb.com

Worcester Polytechnic Institute will hold its second annual Advanced Biomanufacturing Symposium, a two-day, in-depth event that will focus on the technology and processes of continuous biomanufacturing and the challenges of making novel cell and regenerative tissue therapies that are approaching the clinic. The symposium, which was over-subscribed last year, is set for March 27–28, 2017. Organized by WPI life sciences and bioengineering faculty members and the university’s Biomanufacturing Education and Training Center (BETC), the symposium will bring together industry professionals and academic researchers working with new technologies, processes, and business practices that will have a significant impact on biomanufacturing in the near term. “2017 is shaping up to be an important year for biological products, with increasing public awareness of the industry and advances across the biomanufacturing spectrum that will demand our attention,” said Kamal Rashid, PhD, director of the BETC and research professor at WPI. “Evolving platforms and expression systems, progress towards end-to-end continuous biomanufacturing, the challenges of cell and tissue therapies—all of these topics will be explored in detail at our symposium.” This year’s keynote presenters include Manon Cox, PhD, president and chief executive officer of Protein Sciences Corp.; Jerome Ritz, MD, professor at Harvard Medical School and executive director of the Connell and O'Reilly Cell Manipulation and Gene Transfer Laboratory at Dana-Farber Cancer Institute; and Gail Naughton, PhD, chief executive officer of Histogen Inc. Of note, Kelvin Lee, PhD, Gore Professor of Chemical and Biomolecular Engineering at the University of Delaware, who led the team that organized the recently funded National Institute for Innovation in Manufacturing Biopharmaceuticals(NIIMBL), will also speak at the symposium. WPI is a member of NIIMBL. The symposium will feature session talks by subject matter experts from Biogen, Eppendorf, GE Healthcare, MilliporeSigma, Organovo, Pall Life Sciences, Sartorius Stedim Biotech, and Unum Therapeutics, as well as faculty members from Tufts University and WPI. “The talks will be presented in a single-track so participants will have access to all the content, and not have to choose between concurrent sessions,” Rashid said. “This worked very well last year. It helps maximize interaction and information exchange.” (Click here for photos from last year’s symposium. ) The symposium will take place in the Rubin Campus Center on WPI’s campus in Worcester, Mass. Registration is required and space is limited. (Click here for more event information and registration.) Funded in part by a grant from the Massachusetts Life Sciences Center, the BETC is a multi-faceted resource for the biologics industry, providing a range of hands-on customized programs. The BETC works with biomanufacturers to help them train, and retrain, their employees at a state-of-the-art center removed from their own production facilities. The center also provides research collaboration opportunities and consulting services to help companies manage challenges, explore new technologies, or scale up new processes. Founded in 1865 in Worcester, Mass., WPI is one of the nation’s first engineering and technology universities. Its 14 academic departments offer more than 50 undergraduate and graduate degree programs in science, engineering, technology, business, the social sciences, and the humanities and arts, leading to bachelor’s, master’s and doctoral degrees. WPI’s talented faculty work with students on interdisciplinary research that seeks solutions to important and socially relevant problems in fields as diverse as the life sciences and bioengineering, energy, information security, materials processing, and robotics. Students also have the opportunity to make a difference to communities and organizations around the world through the university’s innovative Global Projects Program. There are more than 45 WPI project centers throughout the Americas, Africa, Asia-Pacific, and Europe.


News Article | December 5, 2016
Site: www.eurekalert.org

Future Science Group (FSG) is excited to announce the release of the 10-Year Anniversary Special Focus Issue of Regenerative Medicine entitled "Regenerative medicine: past, present and future", which reflects on how the field has changed in the past 10 years. The special issue takes a look at the past decade in regenerative medicine and provides an overview and perspectives on the progress being made in the field as a whole, as well as in a number of more specific areas including cellular therapy, genome editing, pluripotent stem cell research, ligament regenerative engineering, nanotechnology, immunogenicity and regenerative pharmacology. The issue also provides insight into major institutions involved in the field of regenerative medicine, describing their history, current work and plans for the future. The Special Focus Issue has been guest edited by Robert Lanza (Astellas Institute for Regenerative Medicine, MA, USA), who serves as one of the journal's Associate Editors. Lanza provided a scene-setting foreword for the issue where he looks back at the last decade in regenerative medicine and describes some of the incredible progress made in the field. He then goes on to provide an overview of the wide variety of work presented in the issue including reviews, perspectives and special reports, amongst others. Lanza concludes: "The field of regenerative medicine has continued to grow and change rapidly in the past 10 years. We believe that these articles help highlight important advances that have occurred, and that are likely to impact the future success of the field. The publication of this special issue celebrates an exciting milestone for Regenerative Medicine - the tenth year anniversary of the journal. I hope you will join me in congratulating the journal for reaching this major milestone." Commissioning Editor for Regenerative Medicine Adam Price-Evans commented: "Bursting on to the scene in 2006 with the ALPSP/Charlesworth Award for Best New Journal, Regenerative Medicine has remained at the forefront of the field for the past decade. The journal continues to showcase the latest research and expert commentary from leaders in the field of regenerative medicine and we look forward to the next ten years." Lanza's foreword as guest editor is free to read, here: http://www. Regenerative Medicine is part of the internationally recognized Future Medicine portfolio and is supported by a multidisciplinary, international editorial board comprising leading researchers and opinion leaders from academia and industry, including Senior Editor Chris Mason (UCL, UK), and Associate Editors Phillipe Menasché (Hôpital Européen Georges Pompidou, FR), Gail Naughton (Histogen Inc., CA, USA) and the aforementioned Robert Lanza. Regenerative Medicine focusses on the entire spectrum of approaches in regenerative medicine, including small molecule drugs, biologics, biomaterials, tissue engineering, and cell and gene therapies. The peer-reviewed journal uniquely supports this important area of biomedical science and healthcare by publishing the very best regenerative medicine research and opinion, encompassing all aspects of the sector ranging from discovery research, to clinical development and commercialization. Regenerative Medicine is committed to high-quality scholarly publications, operating a double-blind peer review system, and ensures that all original research and review articles are assessed by a minimum of three experts. It is also committed to supporting authors after publication, and partner with the award-winning Kudos to help authors increase the reach of their published articles. The journal is also partnered with RegMedNet, a free eCommunity aiming to promote global collaboration between all members of the regenerative medicine field as well as keep users up to date with the latest news and opinion, by providing exclusive features, webinars and more. Find out more: http://www. The journal is currently inviting submissions of original research, review and perspective pieces, as well as shorter pieces such as editorials and organizational profiles. Submissions are being accepted via the journal's online submission site. Alternatively, authors are invited to direct any article proposals or general queries to the Commissioning Editor, Adam Price-Evans at a.price-evans@futuremedicine.com. Founded in 2001, London-based FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to the core journal publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, RegMedNet, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. Please see http://www. and http://www. for more information. For additional information on Regenerative Medicine, please contact:


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: STTR PHASE I | Award Amount: 270.00K | Year: 2015

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to overcome limitations that prevent effective treatment of major wound infections. The U.S. spends over $50 billion per year on wound care; thus there is a large potential market for this product. Current wound care products have a high risk of rejection, scarring, and antibiotic resistance. This will be a novel wound care product to reduce the costs to treat infected wounds and limit the number of operations required to restore tissue function. The product consists of a patented human ECM, loaded with a novel anti-infective protein. The main innovation of the proposed product compared to current treatments is that it is designed to be toxic to infective bacteria and other pathogens, without harming human tissue. Furthermore, the human cell-produced material has regenerative and anti-inflammatory activity, may enhance wound healing and improve treatment outcomes. In addition to creating a transformative product in a global market, achievement and assessment of AMP extracellular matrix tethering will lead to a broader understanding of AMP activity and unlock their commercial utility. The product can be used as a temporary wound dressing, a tissue restoring implant, or an implant coating.

The proposed project will utilize a patented recombinant protein with an antimicrobial peptide (cathelicidin-LL37) and a collagen binding domain, combined with a human extracellular matrix (ECM) material. The patented protein is designed to bind collagen in the ECM, and tether the antimicrobial peptide to the material. The research objectives are to improve yield, scalability and purification of antimicrobial protein production, validate the antimicrobial and collagen binding activities of the protein in vitro, measure antimicrobial peptide binding within the ECM material in vitro, and, importantly, to test the efficacy of the antimicrobial peptide-ECM product in vivo. Two in vivo models are proposed; 1) a chick chorioallantoic membrane contaminated with bacteria will be used to test antimicrobial activity, and 2) the material will be implanted in mice to assess its pro-regenerative and anti-inflammatory activity. We anticipate that the antimicrobial peptide will bind to the ECM material, and materials with antimicrobial peptide will exhibit decreased bacterial contamination in vitro and in vivo. The Phase I project team will develop and validate systems for larger scale manufacturing and quality testing of the product in preparation for large animal and human clinical trials.


The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.


The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.


Grant
Agency: National Science Foundation | Branch: | Program: STTR | Phase: Phase I | Award Amount: 225.00K | Year: 2015

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to overcome limitations that prevent effective treatment of major wound infections. The U.S. spends over $50 billion per year on wound care; thus there is a large potential market for this product. Current wound care products have a high risk of rejection, scarring, and antibiotic resistance. This will be a novel wound care product to reduce the costs to treat infected wounds and limit the number of operations required to restore tissue function. The product consists of a patented human ECM, loaded with a novel anti-infective protein. The main innovation of the proposed product compared to current treatments is that it is designed to be toxic to infective bacteria and other pathogens, without harming human tissue. Furthermore, the human cell-produced material has regenerative and anti-inflammatory activity, may enhance wound healing and improve treatment outcomes. In addition to creating a transformative product in a global market, achievement and assessment of AMP extracellular matrix tethering will lead to a broader understanding of AMP activity and unlock their commercial utility. The product can be used as a temporary wound dressing, a tissue restoring implant, or an implant coating. The proposed project will utilize a patented recombinant protein with an antimicrobial peptide (cathelicidin-LL37) and a collagen binding domain, combined with a human extracellular matrix (ECM) material. The patented protein is designed to bind collagen in the ECM, and tether the antimicrobial peptide to the material. The research objectives are to improve yield, scalability and purification of antimicrobial protein production, validate the antimicrobial and collagen binding activities of the protein in vitro, measure antimicrobial peptide binding within the ECM material in vitro, and, importantly, to test the efficacy of the antimicrobial peptide-ECM product in vivo. Two in vivo models are proposed; 1) a chick chorioallantoic membrane contaminated with bacteria will be used to test antimicrobial activity, and 2) the material will be implanted in mice to assess its pro-regenerative and anti-inflammatory activity. We anticipate that the antimicrobial peptide will bind to the ECM material, and materials with antimicrobial peptide will exhibit decreased bacterial contamination in vitro and in vivo. The Phase I project team will develop and validate systems for larger scale manufacturing and quality testing of the product in preparation for large animal and human clinical trials.

Loading Histogen collaborators
Loading Histogen collaborators